Drug Delivery

Scientists Report Gene Expression Pharmacologic Control

Published in Gene Therapy Weekly, September 9th, 1996

Ariad Pharmaceuticals, Inc., Cambridge, Massachusetts, announced the successful demonstration in vivo of a system for precisely controlling the dose of therapeutic proteins delivered by gene therapy.

The ability to increase, decrease, sustain or terminate the expression of a therapeutic gene is considered essential to the clinical utility of many gene therapy strategies.

In a study published in the September 1996 issue of the journal Nature Medicine, a team of Ariad scientists reported for the first time achieving control of a therapeutic gene in vivo by varying the dose of a small-molecule drug. Mice were implanted with engineered cells containing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry